Partner Dan Shores ("Dan") will be a panelist on Monday, April 5, 2021, during the New England Healthcare Executive Network (NEHEN) monthly meeting on "The Future of MRNA Technology: The Next Frontier in Therapeutics."
The development of a COVID-19 vaccine in 11 months to approval condensed decades of messenger RNA research and drug development. From the virus genetic code released in January 2020 scientists at mRNA-based companies quickly designed a vaccine. Beyond the COVID-19 vaccine breakthrough, mRNA offers a newly commercialized approach and therapeutic tool. This groundbreaking technology may open up a wide range of new therapies and markets for infectious disease and other indications for decades to come. Dan will join other industry leaders to discuss trends in mRNA technology, intellectual property, investments, and translation to breakthrough therapies.
Rothwell Figg is proud to be a 2021 sponsor of NEHEN.